Verrica Pharmaceuticals Inc. (VRCA) |
|
6.53 0.32 (5.15%)
|
03-24 16:00 |
|
Open: |
6.21 |
Pre. Close: |
6.21 |
|
High:
|
6.9 |
Low:
|
6.21 |
|
Volume:
|
236,181 |
Market Cap:
|
273(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:31:14 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 9.03 One year: 10.15 |
| Support: |
Support1: 6.17 Support2: 5.14 |
| Resistance: |
Resistance1: 7.73 Resistance2: 8.69 |
| Pivot: |
6.73  |
| Moving Average: |
MA(5): 6.59 MA(20): 6.92
MA(100): 4.57  MA(250): 4.22 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 11.5 %D(3): 20 |
| RSI: |
RSI(14): 47.6 |
| 52-week: |
High: 9.22 Low: 1.76 |
| Average Vol(K): |
3-Month: 189 (K) 10-Days: 138 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VRCA ] has closed above bottom band by 32.5%. Bollinger Bands are 35.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.91 - 6.95 |
6.95 - 6.98 |
|
Low:
|
6.12 - 6.16 |
6.16 - 6.21 |
|
Close:
|
6.46 - 6.53 |
6.53 - 6.59 |
|
Company Description |
|
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. |
Headline News |
Fri, 24 Mar 2023
Analysts Issue Forecasts for Verrica Pharmaceuticals Inc.'s Q2 2023 ... - MarketBeat
Thu, 09 Mar 2023
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 ... - MyChesCo
Thu, 02 Mar 2023
The recent pullback must have dismayed Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders who own 39% of the company - Simply Wall St
Thu, 02 Mar 2023
NOVN: NDA Submitted - Yahoo Finance
Mon, 27 Feb 2023
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Resubmits NDA for ... - Best Stocks
Sun, 29 Jan 2023
Analysts Forecast Verrica Pharmaceuticals Inc. Earnings in the First ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
42 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
39.9 (%) |
|
% Held by Institutions
|
25.9 (%) |
|
Shares Short
|
242 (K) |
|
Shares Short P.Month
|
233 (K) |
Stock Financials |
|
EPS
|
-0.75 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.97 |
|
Profit Margin (%)
|
-271.2 |
|
Operating Margin (%)
|
-235.8 |
|
Return on Assets (ttm)
|
-21.4 |
|
Return on Equity (ttm)
|
-67.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.19 |
|
Sales Per Share
|
0.21 |
|
EBITDA (p.s.)
|
-0.5 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-8.83 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
6.73 |
|
Price to Sales
|
30.26 |
|
Price to Cash Flow
|
-14.66 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
